CTOs on the Move

Oncopeptides

www.oncopeptides.com

 
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Amador Bioscience

Amador Bioscience, a leading partner for successful new drug development, provides global-standard translational sciences and clinical pharmacology services to clients ranging from cutting-edge biotech start-ups to multinational pharmaceutical companies. Founded in 2018 and supported by prominent institutional investors, Amador Bioscience operates in multiple sites, Pleasanton, CA, Ann Arbor, MI, Germantown, MD, Richmond, VA, Hangzhou and Shanghai, China, and Limburg.

Caldera Pharmaceuticals

Caldera Pharmaceuticals is a Los Alamos, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innovative Seating

Innovative Seating Solutions manufactures custom-fitted chairs, back orthotics and seat cushions to relieve pain and enhance seating comfort.

Sanovia

Sanovia s corporate vision is to deliver state-of-the-art products and services which allow its customers to take advantage of advanced technology to improve communications, improve resource utilization through automated workflow processes, advance the quality and appropriateness of care through the integrated use of automated best-practice pharmaceutical clinical guidelines, and control costs.